MX2022012898A - Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta. - Google Patents

Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta.

Info

Publication number
MX2022012898A
MX2022012898A MX2022012898A MX2022012898A MX2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A MX 2022012898 A MX2022012898 A MX 2022012898A
Authority
MX
Mexico
Prior art keywords
solvate
hydrate
pharmaceutically acceptable
acceptable salt
oral administration
Prior art date
Application number
MX2022012898A
Other languages
English (en)
Inventor
Jacqueline Maximilien
Gopal Rajan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2022012898A publication Critical patent/MX2022012898A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona una composición farmacéutica para administración oral que comprende N-(5-(4-(4-((dimetilamino)m etil)-3-fenil-1H-pirazol-1-il)pirimidina-2-ilamino)-4-metoxi-2-mo rfolinofenil)acrilamida o una sal, hidrato o solvato farmacéuticamente aceptable de esta como un ingrediente activo; y una combinación de (i) un derivado de celulosa y (ii) un azúcar o poliol como diluyentes. Las composiciones descritas se caracterizan por una capacidad de fabricación mejorada, mientras se mantienen los beneficios farmacéuticos de minimizar el efecto de acuerdo con cambios en el entorno de pH en el estómago, poseen excelente estabilidad, y exhiben buena biodisponibilidad.
MX2022012898A 2020-04-14 2021-04-13 Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta. MX2022012898A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009623P 2020-04-14 2020-04-14
US202063014277P 2020-04-23 2020-04-23
PCT/IB2021/053035 WO2021209893A1 (en) 2020-04-14 2021-04-13 Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof

Publications (1)

Publication Number Publication Date
MX2022012898A true MX2022012898A (es) 2023-01-24

Family

ID=75562794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012898A MX2022012898A (es) 2020-04-14 2021-04-13 Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta.

Country Status (13)

Country Link
US (1) US20210322323A1 (es)
EP (1) EP4135669A1 (es)
JP (1) JP2023522634A (es)
KR (1) KR20230002656A (es)
CN (1) CN115484937A (es)
AU (1) AU2021257662A1 (es)
BR (1) BR112022020609A2 (es)
CA (1) CA3180184A1 (es)
IL (1) IL297240A (es)
MX (1) MX2022012898A (es)
TW (1) TW202207940A (es)
UY (1) UY39171A (es)
WO (1) WO2021209893A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
EP4349835A1 (en) * 2021-06-01 2024-04-10 Hangzhou Solipharma Co., Ltd. Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof
WO2023138492A1 (zh) * 2022-01-19 2023-07-27 南京明德新药研发有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437006B1 (en) * 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
JP2010507676A (ja) * 2006-10-27 2010-03-11 エフ エム シー コーポレーション 乾式顆粒化結合剤、生成物およびその使用
EP2198857A1 (en) * 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
ES2700231T3 (es) 2012-11-21 2019-02-14 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
US20160151380A1 (en) * 2013-07-12 2016-06-02 The Regents Of The University Of California Therapies for diseases caused by arthropod-borne parasites
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
CN106795144B (zh) 2014-10-13 2020-06-16 株式会社柳韩洋行 用于调节egfr突变体激酶活性的化合物和组合物
EP3439653B1 (en) * 2016-04-07 2021-01-20 ChemoCentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
CA3049452A1 (en) * 2017-01-20 2018-07-26 Gisela Schwab Combinations of cabozantinib and atezolizumab to treat cancer
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors

Also Published As

Publication number Publication date
US20210322323A1 (en) 2021-10-21
EP4135669A1 (en) 2023-02-22
IL297240A (en) 2022-12-01
JP2023522634A (ja) 2023-05-31
UY39171A (es) 2021-10-29
KR20230002656A (ko) 2023-01-05
WO2021209893A8 (en) 2022-10-13
BR112022020609A2 (pt) 2022-11-29
CA3180184A1 (en) 2021-10-21
AU2021257662A1 (en) 2022-12-15
WO2021209893A1 (en) 2021-10-21
TW202207940A (zh) 2022-03-01
CN115484937A (zh) 2022-12-16

Similar Documents

Publication Publication Date Title
MX2022012898A (es) Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta.
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
SE0400284D0 (sv) Novel compounds
WO2021012049A8 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
IN266803B (es)
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
CR20220638A (es) Derivados de amidopirimidona
MX2023014946A (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal.
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
ATE473212T1 (de) Hiv-inhibierende 2-(4-cyanophenyl)-6- hydroxylaminopyrimidine
MX2009007040A (es) Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.
SA523442503B1 (ar) مشتقات سبيروبيبريدينيل مستبدل بأريل غير متجانس واستخدامات صيدلانية لها
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
EA200970570A1 (ru) Макролидные соединения, обладающие противовоспалительной активностью
MX2023008562A (es) Derivados de pirazolamida.
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
NZ543068A (en) Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them
CR20220644A (es) Derivados de sulfona